{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:11Z","timestamp":1790686211212,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.revmed.2022.01.010","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T07:48:04Z","timestamp":1645084084000},"page":"356-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["La leuc\u00e9mie lympho\u00efde chronique"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5338-2071","authenticated-orcid":false,"given":"M.","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.revmed.2022.01.010_bib0325","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.revmed.2022.01.010_bib0330","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood.2019001362","article-title":"Analysis of 153,115\u00a0patients with hematological malignancies refines the spectrum of familial risk","volume":"134","author":"Sud","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.010_bib0335","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3324\/haematol.2008.003632","article-title":"Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia","volume":"94","author":"Goldin","year":"2009","journal-title":"Haematologica"},{"issue":"48","key":"10.1016\/j.revmed.2022.01.010_bib0340","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","article-title":"Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Morton","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"11","key":"10.1016\/j.revmed.2022.01.010_bib0345","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.revmed.2022.01.010_bib0350","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.2016.71.0822","article-title":"Clinical implications of novel genomic discoveries in chronic lymphocytic leukemia","volume":"35","author":"Lazarian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.010_bib0355","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.revmed.2022.01.010_bib0360","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.010_bib0365","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1097\/HS9.0000000000000473","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: recommendations of the French CLL Study Group (FILO)","volume":"4","author":"Quinquenel","year":"2020","journal-title":"HemaSphere"},{"issue":"25","key":"10.1016\/j.revmed.2022.01.010_bib0370","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2020009530","article-title":"Low-burden TP53\u00a0mutations in CLL: clinical impact and clonal evolution within the context of different treatment options","volume":"138","author":"Malcikova","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.revmed.2022.01.010_bib0375","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.revmed.2022.01.010_bib0380","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"van Attekum","year":"2017","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.revmed.2022.01.010_bib0385","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers13153856","article-title":"Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia","volume":"13","author":"Vitale","year":"2021","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.revmed.2022.01.010_bib0390","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.revmed.2022.01.010_bib0395","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1084\/jem.20120833","article-title":"Cellular origin and pathophysiology of chronic lymphocytic leukemia","volume":"209","author":"Seifert","year":"2012","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.revmed.2022.01.010_bib0400","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2020007039","article-title":"Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL","volume":"137","author":"Agathangelidis","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.010_bib0405","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2012.187","article-title":"Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls","volume":"27","author":"Moreira","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.revmed.2022.01.010_bib0410","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19\u00a0in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.010_bib0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/bloodadvances.2021006215","article-title":"Humoral response to mRNA anti-COVID-19\u00a0vaccines BNT162b2\u00a0and mRNA-1273\u00a0in patients with chronic lymphocytic leukemia","volume":"6","author":"Bagacean","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.revmed.2022.01.010_bib0420","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19\u00a0vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.revmed.2022.01.010_bib0425","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/10428194.2017.1330475","article-title":"Regulatory T-cells drive immune dysfunction in CLL","volume":"59","author":"Lad","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.revmed.2022.01.010_bib0430","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3324\/haematol.2011.047316","article-title":"Th17\u00a0and non-Th17\u00a0interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance","volume":"97","author":"Jain","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.010_bib0435","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.revmed.2022.01.010_bib0440","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.010_bib0445","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1056\/NEJMoa075290","article-title":"Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"359","author":"Rawstron","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.010_bib0450","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.revmed.2016.10.396","article-title":"Manifestations auto-immunes et inflammatoires des h\u00e9mopathies lympho\u00efdes","volume":"38","author":"Grignano","year":"2017","journal-title":"Rev Med Interne"},{"issue":"18","key":"10.1016\/j.revmed.2022.01.010_bib0455","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/jnci\/84.18.1422","article-title":"Second cancers in patients with chronic lymphocytic leukemia","volume":"84","author":"Travis","year":"1992","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.010_bib0460","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia","volume":"27","author":"Falchi","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.revmed.2022.01.010_bib0465","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors","volume":"34","author":"Bond","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.revmed.2022.01.010_bib0470","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.revmed.2022.01.010_bib0475","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332\u00a0patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.revmed.2022.01.010_bib0480","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.revmed.2022.01.010_bib0485","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.revmed.2022.01.010_bib0490","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.revmed.2022.01.010_bib0495","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8\u00a0trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.010_bib0500","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.revmed.2022.01.010_bib0505","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.010_bib0510","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.revmed.2022.01.010_bib0515","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood.2020010536","article-title":"The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib","volume":"138","author":"Kittai","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.010_bib0520","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1186\/s12885-019-5971-z","article-title":"Prognostic role of CD4\u00a0T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia","volume":"19","author":"Gauthier","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.revmed.2022.01.010_bib0525","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.leukres.2019.04.016","article-title":"Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology","volume":"81","author":"Zinzani","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.revmed.2022.01.010_bib0530","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279457","article-title":"It is time to adapt anti-CD20\u00a0administration schedule to allow efficient anti-SARS-Cov-2\u00a0vaccination in patients with lymphoid malignancies","author":"Besson","year":"2021","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.revmed.2022.01.010_bib0535","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2\u00a0mRNA COVID-19\u00a0vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.01.010_bib0540","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of BNT162b mRNA Covid19\u00a0Vaccine in patients with chronic lymphocytic leukemia","author":"Benjamini","year":"2021","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.revmed.2022.01.010_bib0545","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.revmed.2022.01.010_bib0550","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1002\/ajh.25480","article-title":"Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group","volume":"94","author":"Quinquenel","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.revmed.2022.01.010_bib0560","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2\u00a0mutations in a real-life CLL cohort still on ibrutinib after 3\u00a0years: a FILO grop stuy","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.revmed.2022.01.010_bib0565","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.010_bib0570","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/hematology.2020000160","article-title":"Evidence-based minireview: treatment of relapsed chronic lymphocytic leukemia after venetoclax","volume":"2020","author":"Thompson","year":"2020","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.revmed.2022.01.010_bib0575","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","article-title":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies","volume":"132","author":"Dreger","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.revmed.2022.01.010_bib0580","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2\u00a0and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.010_bib0585","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.revmed.2022.01.010_bib0590","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib: long-term outcome after ibrutinib in CLL","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"10232","key":"10.1016\/j.revmed.2022.01.010_bib0555","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and o1inutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3\u00a0trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.revmed.2022.01.010_bib0595","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.010_bib0600","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.010_bib0605","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.17788","article-title":"Management of cardiovascular complications of bruton tyrosine kinase inhibitors","volume":"196","author":"Tang","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.revmed.2022.01.010_bib0610","first-page":"230","article-title":"Prise en charge des situations critiques et des risques h\u00e9morragiques chez les patients trait\u00e9s par ibrutinib pour un lymphome","volume":"21","author":"Ysebaert","year":"2015","journal-title":"H\u00e9matologie"},{"issue":"17","key":"10.1016\/j.revmed.2022.01.010_bib0615","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.010_bib0620","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/hematology.2020000120","article-title":"Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia","volume":"2020","author":"Fischer","year":"2020","journal-title":"Hematology"},{"issue":"22","key":"10.1016\/j.revmed.2022.01.010_bib0625","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.revmed.2022.01.010_bib0630","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2\u00a0study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.revmed.2022.01.010_bib0635","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1038\/s41375-021-01280-8","article-title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53\u00a0aberrations","volume":"35","author":"Jain","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.revmed.2022.01.010_bib0320","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood.2020008164","article-title":"A fixed-duration, measurable residual disease\u2013guided approach in CLL: follow-up data from the phase 2\u00a0ICLL-07\u00a0FILO trial","volume":"137","author":"Michallet","year":"2021","journal-title":"Blood"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322000315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322000315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:44:58Z","timestamp":1759337098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866322000315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0248866322000315"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2022.01.010","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La leuc\u00e9mie lympho\u00efde chronique","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2022.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}